BidaskClub Upgrades DexCom, Inc. (DXCM) to “Buy”

DexCom, Inc. (NASDAQ:DXCM) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

Several other research firms also recently commented on DXCM. Royal Bank Of Canada reissued an “outperform” rating and set a $87.00 price objective on shares of DexCom in a report on Tuesday, April 4th. BTIG Research downgraded shares of DexCom from a “buy” rating to a “neutral” rating in a report on Wednesday, May 3rd. Canaccord Genuity dropped their price objective on shares of DexCom from $95.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 3rd. Oppenheimer Holdings, Inc. set a $98.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Wednesday, May 3rd. Finally, Northcoast Research reissued a “buy” rating on shares of DexCom in a report on Wednesday, March 1st. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $90.44.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

DexCom (NASDAQ:DXCM) opened at 78.68 on Wednesday. DexCom has a 12 month low of $57.68 and a 12 month high of $96.38. The firm’s market capitalization is $6.80 billion. The firm’s 50-day moving average is $71.34 and its 200-day moving average is $74.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.06. DexCom had a negative net margin of 14.70% and a negative return on equity of 32.94%. The business had revenue of $142.30 million during the quarter, compared to the consensus estimate of $143.94 million. On average, equities research analysts expect that DexCom will post ($0.70) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was posted by Mideast Time and is owned by of Mideast Time. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.mideasttime.com/bidaskclub-upgrades-dexcom-inc-dxcm-to-buy/1804312.html.

In other DexCom news, EVP Andrew K. Balo sold 3,200 shares of the firm’s stock in a transaction dated Monday, April 10th. The shares were sold at an average price of $78.19, for a total value of $250,208.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard Doubleday sold 3,182 shares of the firm’s stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $75.78, for a total transaction of $241,131.96. Following the completion of the sale, the executive vice president now directly owns 97,815 shares of the company’s stock, valued at approximately $7,412,420.70. The disclosure for this sale can be found here. In the last three months, insiders sold 55,613 shares of company stock valued at $4,033,532. 1.70% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in DXCM. Employees Retirement System of Texas purchased a new stake in shares of DexCom during the fourth quarter valued at about $2,687,000. First Allied Advisory Services Inc. purchased a new stake in shares of DexCom during the fourth quarter valued at about $218,000. Advisory Research Inc. purchased a new stake in shares of DexCom during the fourth quarter valued at about $347,000. Credit Agricole S A purchased a new stake in shares of DexCom during the fourth quarter valued at about $452,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of DexCom during the fourth quarter valued at about $364,000.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:DXCM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.